Demegestone

Demegestone is a medication used to treat Cushing's disease in dogs. It is an inhibitor of the enzyme 3-beta-hydroxysteroid dehydrogenase (3BHSD), which is involved in the production of cortisol, the hormone that causes Cushing's disease. Demegestone reduces the production of cortisol, resulting in a decrease in signs and symptoms of Cushing's disease. It is available as an oral tablet and is usually given twice daily for up to three months. It is also used to treat luteal insufficiency but is now no longer marketed. It is taken by mouth. The most common side effects of demegestone include loss of appetite, vomiting, diarrhea, and lethargy.

Demegestone was a medication belonging to the class of progestins, which are synthetic versions of the natural hormone progesterone. Here's a breakdown of its key features:

Function: Demegestone worked by mimicking progesterone's actions in the body. It interacted with progesterone receptors, primarily affecting the lining of the uterus (endometrium).

Previous Use: It was previously used to treat luteal insufficiency, a condition where the ovaries fail to produce sufficient progesterone during the latter half of the menstrual cycle. This can lead to irregular periods and difficulty getting pregnant.

Discontinued Use: Demegestone is no longer marketed anywhere globally, including France where it was initially introduced.

Key Characteristics:

  • Potency: Compared to natural progesterone, Demegestone was a much stronger progestin, with an estimated potency around 50 times higher in specific tests.
  • Dosage: Depending on the desired outcome, different dosages were administered. Lower doses (around 2.5mg daily) could suppress ovulation, while higher doses (around 100mg per menstrual cycle) impacted the endometrium.
  • No Androgenic Activity: Unlike some progestins that can cause masculinizing side effects due to androgenic properties, Demegestone lacked these effects. It might even possess some antiandrogenic properties.
  • Low Glucocorticoid Activity: Demegestone had minimal interaction with the glucocorticoid receptor, which plays a role in regulating various bodily functions.
Anatomical Therapeutic Chemical Classification
G - Genito-urinary system and sex hormones
G03 Sex hormones and modulators of the genital system
G03D - Progestogens
G03DB Pregnadien derivatives
External Links